Early monotherapy with pegylated interferon alfa–2b for acute hepatitis C infection: Final Results of the German HEP-NET Acute HCV II Study
J Wiegand, P Buggisch, W Böcher, S Zeuzem, CM Gelbmann, T Berg, W Kauffmann, B Kallinowski, M Cornberg, E Jäckel, H Wedemeyer, MP Manns · Zeitschrift für Gastroenterologie · 2006 · Heft 04
Bibliografische Angaben
Zusammenfassung
Introduction: Early treatment of acute hepatitis C with interferon alfa–2b for 24 weeks effectively prevents chronic infection. Since the standard therapy of chronic hepatitis C has changed from conventional to pegylated interferons the aim of this multicenter nation-wide study was to analyze the efficacy of an early treatment with pegylated interferon alfa–2b in patients with acute hepatitis C. Methods: Between February 2001 and February 2004 89 individuals with acute HCV infection were recruited at 53 different centers in Germany. Patients received 1,5µg/kg pegylated interferon alfa–2b s.c. for 24 weeks. End o…
